Salivary Azurocidin and Tumor Necrosis Factor-α Levels in Patients with Stage III-IV, Grade C Periodontitis

Objective: Azurocidin, a neutrophil granule-derived antimicrobial protein, plays an important role in host-pathogen interactions and immunoregulation. Periodontitis is a polymicrobial inflammatory disease caused by the host response to subgingival microbiota. This study aimed to evaluate salivary azurocidin and tumor necrosis factor (TNF)-α levels in patients with stage III-IV, grade C periodontitis.Methods and Materials: In total 78 systemically healthy individuals (40 periodontitis (stage III-IV, grade C) and 38 periodontally healthy) were enrolled. Saliva samples were collected and clinical periodontal measurements including probing depth (PD), cli nical attachment loss (CAL), the percentage of sites with bleeding on probing (BOP %), gingival index (GI) and plaque index (PI) were recorded. Salivary azurocidin and TNF-α levels were measured by ELISA.Results: Periodontitis group exhibited higher PD, CAL, BOP (%), GI and PI values compared to the periodontally healthy group (p

PDF

___

1. FlemmigTF.Periodontitis.AnnPeriodontol1999;4:32-38.

2.Kinane DF, Preshaw PM, Loos BG. Host- response: understanding the cellular and molecular mechanisms of host-microbial interactions-- consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol 2011;38 Suppl 11:44-48.

3.Mombelli A. Microbial colonization of the periodontal pocket and its significance for periodontal therapy. Periodontol 2000 2018;76:85-96.

4.Herrmann JM, Meyle J. Neutrophil activation and periodontal tissue injury. Periodontol 2000 2015;69:111-127.

5.Gorr SU, Abdolhosseini M. Antimicrobial peptides and periodontal disease.J Clin Periodontol2011;38 Suppl 11:126-141.

6.Türkoğlu O, Emingil G, Kütükçüler N,AtillaG. Evaluation of gingival crevicular fluid adrenomedullin and human neutrophil peptide 1-3 levels of patients with different periodontal diseases. J Periodontol2010;81:284-291.

7.Ertugrul AS, Sahin H, Dikilitas A, Alpaslan NZ, Bozoğlan A, Tekin Y. Gingival crevicular fluid levels of human beta-defensin-2 and cathelicidin in smoker and non-smoker patients: a cross-sectional study. J Periodontal Res2014;49:282-289.

8.Tapper H, Karlsson A, Mörgelin M, Flodgaard H, Herwald H. Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles. Blood 2002;99:1785-1793.

9.Soehnlein O, Lindbom L. Neutrophil-derived azurocidin alarms the immune system. J Leukoc Biol 2009;85:344-351.

10.Almeida RP, Vanet A, Witko-Sarsat V, Melchior M, McCabe D, Gabay JE. Azurocidin, a natural antibiotic from human neutrophils: expression, antimicrobial activity, and secretion. Protein Expr Purif1996;7:355-366.

11.Heinzelmann M, Platz A, Flodgaard H, Polk HC Jr, Miller FN. Endocytosis of heparin-binding protein (CAP37) is essential for the enhancement of lipopolysaccharide-induced TNF-alpha production in human monocytes. J Immunol 1999;162:4240-4245.

12.Linder A, Arnold R, Boyd JH, Zindovic M, Zindovic I, Lange A et al. Heparin-Binding Protein Measurement Improves the Prediction of Severe Infection With Organ Dysfunction in the Emergency Department. Crit Care Med2015;43:2378-2386.

13.Caseiro A, Ferreira R, Quintaneiro C, Pereira A, Marinheiro R, Vitorino R et al. Protease profiling of different biofluids in type 1 diabetes mellitus. Clin Biochem 2012 ;45:1613-1619.

14.Leppilahti JM, Hernández-Ríos PA, Gamonal JA, Tervahartiala T, Brignardello-Petersen R, Mantyla P et al. Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid provide site-specific diagnostic value for chronic periodontitis. J Clin Periodontol2014;41:348-356.

15.Choi YJ, Heo SH, Lee JM, Cho JY. Identification of azurocidin as a potential periodontitis biomarker by a proteomic analysis of gingival crevicular fluid. Proteome Sci2011;28;9:42.

16.Guzman YA, Sakellari D, Papadimitriou K, FloudasCA. High-throughput proteomic analysis of candidate biomarker changes in gingival crevicular fluid after treatment of chronic periodontitis. J Periodontal Res2018;53:853-860.

17.Podzimek S, Vondrackova L, Duskova J, Janatova T, Broukal Z. Salivary Markers for Periodontal and General Diseases.Dis Markers2016;2016:9179632.

18.Ghallab NA. Diagnostic potential and future directions of biomarkers in gingival crevicular fluid and saliva of periodontal diseases: Review of the current evidence.Arch Oral Biol2018;87:115-124.

19.Teles RP, Likhari V, Socransky SS, Haffajee AD. Salivary cytokine levels in subjects with chronic periodontitis and in periodontally healthy individuals: a cross-sectional study. J Periodontal Res2009;44:411-417

20.Newbrun E. Indices to measure gingival bleeding. J Periodontol1996;67:555-561.

21.Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of victamine C. J Periodontol1970;41:41-43.

22.Tonetti MS, Sanz M. Implementation of the new classification of periodontal diseases: Decision- making algorithms for clinical practice and education. J Clin Periodontol2019;46:398-405.

23.Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci1993;694:72-77.

24.Denny P, Hagen FK, Hardt M, Liao L, Yan W, Arellanno M et al. The proteomes of human parotid and submandibular/sublingual gland salivascollected as the ductal secretions. J Proteome Res 2008;7:1994-2006.

25.Preshaw PM, Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? J Clin Periodontol 2011;38 Suppl 11:60-84.

26.Frodge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodeling biomarkers of periodontal disease in saliva. J Periodontol 2008;79:1913-1919.

27.Gümüş P, Nizam N, Lappin DF, Buduneli N. Saliva and serum levels of B-cell activating factors and tumor necrosis factor-α in patients with periodontitis. J Periodontol2014;85:270-280.